Cargando…

Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium

Background: Routine human papillomavirus (HPV) immunization in Belgium is currently regionally managed, with school-aged girls receiving the 9-valent HPV (9vHPV) vaccine in Flanders and Wallonia-Brussels with a national catch-up program for females only. This study will assess whether expanding thes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simoens, Steven, Bento-Abreu, Andre, Merckx, Barbara, Joubert, Sophie, Vermeersch, Steve, Pavelyev, Andrew, Varga, Stefan, Morais, Edith
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072375/ https://www.ncbi.nlm.nih.gov/pubmed/33912045 http://dx.doi.org/10.3389/fphar.2021.628434

Ejemplares similares

Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland
por: Kind, André B., et al.
Publicado: (2020)

Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
por: Cheung, Tak Hong, et al.
Publicado: (2023)

The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong
por: Cheung, Tak Hong, et al.
Publicado: (2021)

Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
por: Barbier, Liese, et al.
Publicado: (2022)

Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
por: Vandenplas, Yannick, et al.
Publicado: (2021)

Not one, but many: developing a multi-indication pricing model for medicines in Belgium
por: Maes, Ingrid, et al.
Publicado: (2023)

A Broad Safety Assessment of the 9-Valent Human Papillomavirus Vaccine
por: Yih, W Katherine, et al.
Publicado: (2021)

Systemic lupus erythematosus following human papillomavirus 9-valent vaccination
por: Wan, Yuehua, et al.
Publicado: (2022)

Extended surveillance to assess safety of 9-valent human papillomavirus vaccine
por: Sundaram, Maria E., et al.
Publicado: (2022)

How to balance valuable innovation with affordable access to medicines in Belgium?
por: Simoens, Steven, et al.
Publicado: (2022)

The epidemiologic and economic impact of a quadrivalent human papillomavirus vaccine in Thailand
por: Termrungruanglert, Wichai, et al.
Publicado: (2021)

Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
por: Serrano, Beatriz, et al.
Publicado: (2012)

Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials
por: Costa, Ana Paula Ferreira, et al.
Publicado: (2017)

Public health impact and return on investment of Belgium’s pediatric immunization program
por: Carrico, Justin, et al.
Publicado: (2023)

Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied
por: Vänskä, Simopekka, et al.
Publicado: (2020)

Re-Analysis of Modeling a Switch from a 13-Valent to 10-Valent Pneumococcal Conjugate Vaccine in Canada: Leveraging Real-World Experience from Belgium
por: Wasserman, Matt D., et al.
Publicado: (2018)

Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices
por: Petrosky, Emiko, et al.
Publicado: (2015)

Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence
por: SIGNORELLI, C., et al.
Publicado: (2017)

Off-Label 9-Valent Human Papillomavirus Vaccination for Actinic Keratosis: A Case Series
por: Wenande, Emily, et al.
Publicado: (2021)

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
por: Garland, Suzanne M., et al.
Publicado: (2022)

Costs and Cost-Effectiveness of 9-Valent Human Papillomavirus (HPV) Vaccination in Two East African Countries
por: Kiatpongsan, Sorapop, et al.
Publicado: (2014)

Association of Inadvertent 9-Valent Human Papillomavirus Vaccine in Pregnancy With Spontaneous Abortion and Adverse Birth Outcomes
por: Kharbanda, Elyse O., et al.
Publicado: (2021)

Systemic 9-valent human papillomavirus vaccine for recalcitrant common cutaneous warts in preparation for renal transplant
por: Wyant, W. Austin, et al.
Publicado: (2022)

Safety of 4-valent human papillomavirus vaccine in males: a large observational post-marketing study
por: Amend, Kandace L., et al.
Publicado: (2022)

Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine Types
por: Nolan, Katrina M., et al.
Publicado: (2023)

Myasthenia gravis after the third dose of human papillomavirus 9-valent vaccine: A case report
por: Ding, Yuan, et al.
Publicado: (2023)

Spotlight on the 9-valent HPV vaccine
por: Lopalco, Pier Luigi
Publicado: (2016)

Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review
por: Mahumud, Rashidul Alam, et al.
Publicado: (2020)

Otitis media in children vaccinated during consecutive 7-valent or 10-valent pneumococcal conjugate vaccination schedules
por: Leach, Amanda Jane, et al.
Publicado: (2014)

Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico
por: Wasserman, Matthew, et al.
Publicado: (2018)

Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
por: Haggenburg, Sabine, et al.
Publicado: (2023)

Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age
por: Moreira, E. D., et al.
Publicado: (2017)

Immunogenicity correlation in cynomolgus monkeys between Luminex‐based total IgG immunoassay and pseudovirion‐based neutralization assay for a 14‐valent recombinant human papillomavirus vaccine
por: Bei, Lei, et al.
Publicado: (2022)

Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up
por: Kjaer, Susanne K., et al.
Publicado: (2020)

Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women()
por: Ruiz-Sternberg, Ángela María, et al.
Publicado: (2017)

Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries
por: Garland, S M, et al.
Publicado: (2018)

Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles
por: Wang, Daning, et al.
Publicado: (2020)

Correction: Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review
por: Mahumud, Rashidul Alam, et al.
Publicado: (2023)

Effect of 10-Valent Pneumococcal Vaccine on Pneumonia among Children, Brazil
por: Afonso, Eliane Terezinha, et al.
Publicado: (2013)

Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia
por: Sundaram, Neisha, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6hhnan33tpfrohc32h9cth1fhh